{"id":"https://openalex.org/W21501481","doi":null,"title":"PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.","display_name":"PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.","alternate_titles":[],"publication_year":2010,"publication_date":"2010-06-01","ids":{"openalex":"https://openalex.org/W21501481","mag":"21501481","pmid":"https://pubmed.ncbi.nlm.nih.gov/20496265"},"language":"en","primary_location":{"id":"pmid:20496265","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20496265","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W21501481"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059758317","display_name":"Keiran S.M. Smalley","orcid":"https://orcid.org/0000-0003-1089-9307","observed_orcids":["https://orcid.org/0000-0003-1089-9307","https://orcid.org/0000-0002-4121-8335"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Keiran S M Smalley","raw_affiliation_strings":["The Moffitt Cancer Center, Programs of Molecular Oncology and Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL, 33612, USA. keiran.smalley@moffitt.org"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Moffitt Cancer Center, Programs of Molecular Oncology and Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL, 33612, USA. keiran.smalley@moffitt.org","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5059758317"],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":null,"apc_paid":null,"fwci":4.3726,"has_fulltext":false,"cited_by_count":77,"citation_normalized_percentile":{"value":0.95945334,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"11","issue":"6","first_page":"699","last_page":"706"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9539999961853027},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.7829999923706055},{"id":"https://openalex.org/keywords/small-molecule-kinase-inhibitors","display_name":"small-molecule kinase inhibitors","score":0.6919999718666077},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.7549999952316284},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8569999933242798},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.4690000116825104}],"concepts":[{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7312010526657104},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6659629940986633},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6252694129943848},{"id":"https://openalex.org/C2776470698","wikidata":"https://www.wikidata.org/wiki/Q21851559","display_name":"V600E","level":4,"score":0.6044924259185791},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5823991894721985},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5290939807891846},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.4321577250957489},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.41525518894195557},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.3457372784614563},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3254217505455017},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18401983380317688},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.06709948182106018},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077484","descriptor_name":"Vemurafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:20496265","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20496265","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:21501481","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20496265","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W1623301431"],"related_works":["https://openalex.org/W1971947883","https://openalex.org/W1414915294","https://openalex.org/W1560370693","https://openalex.org/W2106543129","https://openalex.org/W2145358298","https://openalex.org/W2411744888","https://openalex.org/W2154196978","https://openalex.org/W2018816799","https://openalex.org/W1970845550","https://openalex.org/W1969473082"],"abstract_inverted_index":{"PLX-4032":[0,63,89,112],"is":[1,32],"a":[2,180],"small-molecule,":[3],"orally":[4],"available":[5],"B-Raf":[6,73,178],"kinase":[7,58],"inhibitor":[8],"being":[9],"developed":[10],"by":[11],"Plexxikon":[12],"Inc":[13],"and":[14,64,90,104,116,135,138,162,165],"Hoffman-La":[15],"Roche":[16],"Ltd":[17],"for":[18,78,177],"the":[19,79,83,94,175],"treatment":[20],"of":[21,30,72,96,132,149],"cancers":[22],"harboring":[23],"activating":[24,38],"BRAF":[25,39,52],"mutations.":[26],"The":[27],"primary":[28],"focus":[29],"development":[31],"in":[33,102,105,121,140,183],"melanoma":[34,98],"(>":[35,49],"50%":[36],"harbor":[37,51],"mutations)":[40],"with":[41,75,124,130],"other":[42],"solid":[43],"tumors,":[44],"such":[45],"as":[46,179],"colorectal":[47],"carcinoma":[48],"10%":[50],"mutations),":[53],"also":[54],"under":[55],"investigation.":[56],"Purified":[57],"assays":[59],"have":[60],"demonstrated":[61],"that":[62,155],"its":[65,91],"related":[66],"analogs":[67,92],"are":[68,169],"highly":[69],"potent":[70],"inhibitors":[71],"activity,":[74],"3-fold":[76],"selectivity":[77],"V600E":[80],"mutation":[81],"over":[82],"wild-type":[84],"kinase.":[85],"In":[86,107],"preclinical":[87],"models,":[88],"inhibited":[93],"growth":[95],"BRAFV600E-positive":[97,125],"cell":[99,136],"lines":[100],"both":[101],"vitro":[103],"vivo.":[106],"phase":[108,151,163],"I":[109,152],"clinical":[110,167],"trials,":[111],"was":[113,158],"well":[114,129],"tolerated":[115],"objective":[117],"responses":[118],"were":[119],"observed":[120],"several":[122],"patients":[123],"tumors.":[126],"Responses":[127],"correlated":[128],"inhibition":[131],"intratumoral":[133],"phospho-ERK":[134],"proliferation,":[137],"reductions":[139],"fluorodeoxyglucose":[141],"uptake":[142],"on":[143],"PET":[144],"scanning.":[145],"A":[146],"preliminary":[147],"analysis":[148],"this":[150],"data":[153],"suggested":[154],"progression-free":[156],"survival":[157],"approximately":[159],"7":[160],"months,":[161],"II":[164],"III":[166],"trials":[168],"now":[170],"underway.":[171],"These":[172],"studies":[173],"provide":[174],"proof-of-concept":[176],"therapeutic":[181],"target":[182],"melanoma.":[184]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W21501481","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":14}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
